Clinical Trials Logo

Lobular Breast Carcinoma clinical trials

View clinical trials related to Lobular Breast Carcinoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06067503 Recruiting - Breast Cancer Clinical Trials

Biomarkers to Detect Endocrine Therapy Resistance

Start date: April 30, 2024
Phase: Phase 2
Study type: Interventional

This pilot observational study is being done to identify possible biomarkers of response to endocrine therapy in patients with ER/PR+ metastatic lobular breast cancer (LBC) starting new endocrine therapy. 18F-fluorofuranylnorprogesterone Positron Emission Tomography/Computed Tomography (FFNP-PET/CT) and liquid biopsies will be performed at baseline and after 4 weeks of treatment. Baseline levels and dynamic on-treatment changes in estrogen signaling as measured by FFNP-PET/CT and circulating tumor cell (CTC) liquid biopsy will be correlated with clinical response to endocrine therapy and progression-free survival in the above cohort of patients.

NCT ID: NCT05964504 Recruiting - Clinical trials for Metastatic Breast Cancer

Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)

Start date: December 20, 2024
Phase:
Study type: Observational [Patient Registry]

This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response assessment tool.

NCT ID: NCT05931302 Recruiting - Clinical trials for Lobular Breast Carcinoma

Initial Staging of Lobular Breast Carcinoma: Head to Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT

GALILEE
Start date: November 16, 2023
Phase: N/A
Study type: Interventional

Lobular Breast cancer staging with 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) is not optimal due to the poor accumulation of 18F-FDG in the tumour. Through better sensitivity (and specificity), 68Ga-FAPI-46-46 PET should provide a more accurate staging of lobular breast cancer than 18F-FDG PET.

NCT ID: NCT05837767 Recruiting - Pancreatic Cancer Clinical Trials

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

Start date: July 24, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to find out whether lattice radiation therapy (LRT) is an effective radiation therapy technique when compared to standard stereotactic body radiation therapy (SBRT). The study will also study how the different radiation therapy techniques (LRT and SBRT) affect how many immune cells are able to attack and kill tumor cells (immune infiltration).

NCT ID: NCT05410951 Recruiting - BRCA1 Mutation Clinical Trials

LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients

LobularCard
Start date: May 16, 2022
Phase:
Study type: Observational

This is a cross-sectional and retrospective study of a cohort of patients with invasive lobular breast cancer (LBC) or in situ lobular neoplasia (LIN3). The main endpoint is the relative frequency of patients with a germline mutation using a recent panel including 113 genes from the "Illumina" protocol. In case of identification of a novel pathogenetic germline mutations, a personalized follow-up will be offered to each patient (in case of genes at moderate-, low-penetrance), or prophylactic mastectomy (in case of genes at high-penetrance). Breast screening in moderate-, low-penetrance mutated patients should be performed periodically using digital mammography, ultrasound and MRI, and will be routinely observed. Patients will be scheduled for follow-up at six-month intervals for 5 years at our outpatient clinic, and yearly thereafter